Compare ARCT & IPHA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ARCT | IPHA |
|---|---|---|
| Founded | 2013 | 1999 |
| Country | United States | France |
| Employees | N/A | 163 |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 198.1M | 165.3M |
| IPO Year | 2019 | N/A |
| Metric | ARCT | IPHA |
|---|---|---|
| Price | $5.52 | $1.78 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 10 | 4 |
| Target Price | ★ $24.11 | $5.75 |
| AVG Volume (30 Days) | ★ 564.0K | 6.3K |
| Earning Date | 05-07-2026 | 03-26-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 20.00 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $82,031,000.00 | N/A |
| Revenue This Year | N/A | $180.36 |
| Revenue Next Year | $12.77 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $5.74 | $1.18 |
| 52 Week High | $24.14 | $2.63 |
| Indicator | ARCT | IPHA |
|---|---|---|
| Relative Strength Index (RSI) | 26.97 | 52.60 |
| Support Level | N/A | $1.73 |
| Resistance Level | $7.98 | $1.96 |
| Average True Range (ATR) | 0.36 | 0.05 |
| MACD | -0.10 | -0.00 |
| Stochastic Oscillator | 0.23 | 39.78 |
Arcturus Therapeutics Holdings Inc is an RNA medicines company focused on the development of infectious disease vaccines and opportunities within liver and respiratory rare diseases. It operates in one business segment, which includes all activities related to the discovery, development, and commercialization of messenger RNA medicines. The company's pipeline includes LUNAR-OTC and LUNAR-CF. Its Vaccine candidates include LUNAR-FLU, KOSTAIVE XBB.1.5, KOSTAIVE, and Others.
Innate Pharma SA is a clinical-stage biotechnology company. It is engaged in developing immunotherapies for cancer patients. The company's approach includes therapeutic modalities such as monoclonal antibodies, multispecific NK cell engagers through its ANKET platform, and antibody-drug conjugates (ADC). Its portfolio includes lacutamab, which is being studied for cutaneous T-cell lymphomas and peripheral T-cell lymphomas, and monalizumab, which is being developed in collaboration with AstraZeneca for non-small cell lung cancer. The company's revenue mainly consists of revenues from collaboration and licensing agreements and government financing for research expenditure in the form of research tax credits, as well as other grants.